Sept 2011: UK study on new CMV treatment gets funding

     
At the moment the main treatment available for congenital CMV  is Ganciclovir. However it is an invasive treatment for a newborn baby (it is administered via intraveinous drip), and in some cases it can cause adverse effects. Also, Ganciclovir treatment must be started before a baby is 4 weeks old, leaving a very small window  of opportunity to combat the possible effects of CMV, especially if it is not diagnosed immediately at birth. [singlepic id=59 w=250 float=left]A new study has just been awarded funding to test a less invasive oral antiviral called Valganciclovir. The study will  test 6 weeks of valgancyclovir treatment in infants aged 1-18 months old, significantly increasing the potential window for treating congenital CMV. Please email info@cmvaction.org.uk if you are interested in finding out more. &;

Tags: 

  • news
     

Our Stories

Lewis was born 3 weeks early on 23rd December 1997 following a normal healthy pregnancy. The labour was not easy, but relatively quick being 4 hours in total but he was in distress and... Read more
This is our Evalyn Rose, she was a long awaited baby.  My husband and I were told we could not have any more children due to fertility issues, we tried a round of fertility treatment... Read more

Registered charity no: 1171773